5 FDA decisions to watch in the fourth quarter of 2026

Published 01 Oct 2026, 13:15 UTC. Updated 01 Oct 2026, 20:02 UTC.

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

Directly affected

GSK Gsk
Named in this report.

Indirectly affected

ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.

Price reaction, T-5 to T+3

Ticker	T-5	T-3	T-1	T0	T+1	T+2	T+3
GSK	—	—	—	—	—	—	—
ACHC	—	—	—	—	—	—	—
ASND	—	—	—	—	—	—	—
ATYR	—	—	—	—	—	—	—
BBIO	—	—	—	—	—	—	—
CRDF	—	—	—	—	—	—	—
DVA	—	—	—	—	—	—	—

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

Source: BioPharma Dive

How far Acadia Healthcare (ACHC) has moved since 1 Oct 2026

Since the first closing price after “5 FDA decisions to watch in the fourth quarter of 2026,” Acadia Healthcare (ACHC) is +7.66%. The S&P 500 fund (SPY) is -0.40% over the same days, a +8.06% difference versus the market.

ACHC

SPY

Filings that name Acadia Healthcare (ACHC) around 1 Oct 2026

Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 2 days before publication, inside 30 days. The filing is listed beside the story “5 FDA decisions to watch in the fourth quarter of 2026.”

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who is named in “5 FDA decisions to watch in the fourth quarter of 2026”

Companies mentioned with this story

ACHC Acadia Healthcare
For “5 FDA decisions to watch in the fourth quarter of 2026,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 1 Oct 2026 story “5 FDA decisions to watch in the fourth quarter of 2026.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ATYR aTYR PHARMA
In “5 FDA decisions to watch in the fourth quarter of 2026,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
BBIO BridgeBio Pharma
In “5 FDA decisions to watch in the fourth quarter of 2026,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
CRDF Cardiff Oncology
In “5 FDA decisions to watch in the fourth quarter of 2026,” Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence. Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 1 Oct 2026 story “5 FDA decisions to watch in the fourth quarter of 2026.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

How “5 FDA decisions to watch in the fourth quarter of 2026” reaches Acadia Healthcare (ACHC)

“5 FDA decisions to watch in the fourth quarter of 2026” (1 Oct 2026) reaches Acadia Healthcare (ACHC) through this story.

What ties Acadia Healthcare (ACHC) to the headline is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Also listed, Ascendis Pharma A/S (ASND): GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Price levels for Acadia Healthcare (ACHC)

ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.

How solid “5 FDA decisions to watch in the fourth quarter of 2026” looks

46 out of 100

“5 FDA decisions to watch in the fourth quarter of 2026” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.